Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDEAL study of enasidenib in IDH2-mutated myelodysplastic syndrome
2024-513858-29-01Phase 2Authorised
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of enasidenib in myelodysplastic syndrome (MDS) (3 cohorts), sponsored by Groupe Français des Myélodysplasies. Primary endpoints: Overall hematological response at 3 and 6 months and Safety for cohort C. Planned start Dec 2024; status: authorised.
02
Drugs
enasidenib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2024-513858-29-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513858-29-01.